SCHEMBL1744944

SCHEMBL1744944

COC(=O)CCc1ccc(OCc2sc3ccccc3c2OCc2ccccc2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 12/20 0.47
FFAR4 Q5NUL3 6/20 0.47
AKR1B1 P15121 1/20 0.43
VDR P11473 2/20 0.43
MAOB P27338 1/20 0.43
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
PPARD Q03181 1/20 0.41
S1PR1 P21453 1/20 0.40
S1PR5 Q9H228 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746796 0.90 FFAR1 (0.59) FFAR1FFAR4AKR1B1THRATHRB
SCHEMBL1747352 0.86 VDR (0.41) FFAR1FFAR4AKR1B1VDRPPARD
SCHEMBL1746798 0.84 VDR (0.46) FFAR1FFAR4AKR1B1VDRPPARD
SCHEMBL1746635 0.81 MAPT (0.45) FFAR1FFAR4AKR1B1VDRPPARD
SCHEMBL1745138 0.77 FFAR1 (0.52) FFAR1FFAR4AKR1B1
SCHEMBL1744783 0.76 FFAR1 (0.48) FFAR1FFAR4AKR1B1VDRPPARD
SCHEMBL1744466 0.74 FFAR1 (0.75) FFAR1FFAR4AKR1B1VDRPPARD
SCHEMBL2828461 0.74 FFAR1 (0.54) FFAR1FFAR4AKR1B1VDR
SCHEMBL1746851 0.74 L3MBTL1 (0.41) MAOBTHRATHRBL3MBTL1
SCHEMBL1744932 0.73 FFAR1 (0.56) FFAR1FFAR4AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885AKR1B1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.